Sector News

Boehringer, OSE tie up in I-O deal that could total more than $1.4B

April 5, 2018
Life sciences

Boehringer Ingelheim and OSE Immunotherapeutics are partnering to develop the latter’s checkpoint inhibitor, OSE-172, for the treatment of advanced solid tumors. The candidate, a SIRP-alpha antagonist targeting myeloid lineage cells, is currently in preclinical studies in various cancers.

For the global rights to OSE-172, Boehringer will hand over €15 million ($18.4 million), with another €15 million to follow when the treatment hits phase 1. On top of that, OSE stands to collect royalties on worldwide net sales, as well as more than €1.1 billion in preset development, commercialization and sales milestones, the companies said.

“We are excited to partner with OSE Immunotherapeutics to develop this promising, novel cancer immunotherapy,” said Jonathon Sedgwick, Ph.D., global head of cancer immunology and immune modulation research at Boehringer Ingelheim. “A key area of focus is the identification of drugs that target myeloid cell immune regulatory receptors of which SIRP-alpha is a leading example. We are dedicated to developing ground-breaking, first-in-class therapies that can transform the lives of patients and help win the fight against cancer.”

OSE-172 is a monoclonal antibody that targets SIRP-alpha, a receptor expressed in myeloid lineage cells, including dendritic cells, tumor-associated macrophages and myeloid-derived suppressor cells. It blocks the CD47 ligand from binding to and activating SIRP-alpha and could potentially boost antitumor immunity by ramping up the activity of myeloid lineage cells.

OSE has a number of partnerships to advance its pipeline. These include a development and commercialization deal with Servier around its interleukin-7 antagonist targeting autoimmune disease worth up to $283 million and a research collaboration with Memorial Sloan Kettering to assess the potential of OSE-703, its anti-CD127 antibody, to treat non-small cell lung cancer (NSCLC) and other solid tumors. Back in July 2016, Janssen took the option to license OSE’s anti-CD28 monoclonal antibody, FR104, in autoimmune diseases after positive phase 1 data.

By Amirah Al Idrus

Source: Fierce Biotech

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).